|
|
PI-RI |
|
Vaxjo ID |
184 |
|
Vaccine Adjuvant Name |
PI-RI |
|
Alternative Names |
RIBI natural |
|
Adjuvant VO ID |
VO_0005782
|
|
Description |
combination adjuvant that is TLR4, NOD1 agonist that induces mixed Th1/Th2 response; designed as an alternative to no longer commercially available RIBI adjuvant |
|
Stage of Development |
Research |
|
Location Licensed |
US (Pai Life sciences Seattle, WA) |
|
Host Species for Testing |
6 |
|
Components |
monophosphoryl lipid A [MPL] + trehalose 6,6′ -dimycolate [TDM] + cell wall skeleton from Mycobacterium phlei [CWS] |
|
Storage |
2-8C |
|
Function |
innate immune activation |
| References |
(Carter, 2025): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=23]
Lukehart et al., 2022: Lukehart SA, Molini B, Gomez A, Godornes C, Hof R, Fernandez MC, Pitner RA, Gray SA, Carter D, Giacani L, Cameron CE. Immunization with a tri-antigen syphilis vaccine significantly attenuates chancre development, reduces bacterial load, and inhibits dissemination of Treponema pallidum. Vaccine. 2022; 40(52); 7676-7692. [PubMed: 36376214].
|
|
